Skip Navigation Genome.gov - National Human Genome Research InstituteGenome.gov - National Human Genome Research InstituteGenome.gov - National Human Genome Research InstituteNational Institutes of Health
   
       Home | About NHGRI | Newsroom | Staff
Research Grants Health Policy & Ethics Educational Resources Careers & Training
Current News Releases

NHGRI-Related News

Press Photos

Broadcast Media

NHGRI Webcasts

NHGRI Podcasts

Media Resources

Media Contacts

Calendar of Events

News Release Archives
(1994-2008)

Recent Articles
from NHGRI


Speeches and Testimony


In Other Sections:

50 years of DNA: A Celebration of the Genome

Science, Research Technique and Institute Fact Sheets

Online Health Resources



Home>Newsroom >Current News Releases
Print Version


Current News Releases

RSS Web Feed | What's this?

March
February

2009

March

March 2, 2009: Low Levels of Vitamin B12 May Increase Risk for Neural Tube Defects New
Children born to women who have low blood levels of vitamin B12 shortly before and after conception may have an increased risk of a neural tube defect, according to an analysis by researchers at the National Institutes of Health, Trinity College Dublin, and the Health Research Board of Ireland. Women with the lowest B12 levels had 5 times the risk of having a child with a neural tube defect compared to women with the highest B12 levels.

February

February 18, 2009: Could Genetics Improve Warfarin Dosing? New
In a large-scale study and an upcoming clinical trial, scientists supported by the National Institutes of Health address one of the trickiest issues in prescribing medicine — how to quickly optimize each patient's dosage of the common blood-thinning drug warfarin. Using information from thousands of genetically and geographically diverse patients, an international team of researchers, funded in part by the National Human Genome Research Institute, has developed a way to use genetic information from patients that could help doctors better determine optimal warfarin doses. The results of the analysis are published in an article titled "Warfarin Dosing Using Clinical and Pharmacogenetic Data" in the Feb. 19 issue of The New England Journal of Medicine.

February 2, 2009: New Findings Raise Questions About Process Used to Identify Experimental Drug for Rare Genetic Diseases New
A study by National Institutes of Health (NIH) researchers reveals surprising new insights into the process used to initially identify an experimental drug now being tested in people with cystic fibrosis and muscular dystrophy. Researchers emphasized that the clinical implications of their findings are unclear, but said the results suggest more work may be needed to make sure the screening process to select promising agents was not flawed by its effects on a firefly enzyme used as a marker.


Last Updated: March 2, 2009



PrivacyCopyrightContactAccessibilitySite MapStaff DirectoryFOIAHome Department of Health and Human Services  National Institutes of Health  USA.gov